The effect of metformin vs placebo on sex hormones in CCTG MA.32. Dr. Ana Lohmann et al. 

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. Dr. Ana Lohmann et al. 

Obesity and Breast Cancer: Expanding the Hypothesis Space. Dr. Ana Lohmann et al. 

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oliogometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trials. Dr. David A. Palma et al. 

Human Papillomavirus E7 Oncoprotein targets RNF168 to hijack the host DNA damage response. J. Mymryk et al. 

Influenza Vaccine Effectiveness Among Patients with Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data from Ontario, Canada. Dr. P. Blanchette et al. 

Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yarembo B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu N, Moore K, Currie S, Bauman G, Warner A, Plama D. Quality of life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trail. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):943-947. doi: 10.1016/j.ijrobp.2019.08.041 Epub 2019 Aug 27.

Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, Rodrigues GB, Lock M, Yaremko BP, Bauman GS, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthi S, Louie AV, Swaminath A, Chalmers A, Warner A, Slotman BJ, de Gruijl TD, Allan A, Senan S.
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.

Guidolin K, Yaremko B, Lynn K, Gaede S, Kornecki A, Muscedere G,BenNachum I, Shmuilovich O, Mouawad M, Yu E, Sexton T, Gelman N, Moiseenko V, Brackstone M, Lock M. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy. Curr Oncol. 2019 Jun;26(3):e334-e340. doi: 10.3747/co.26.4479. Epub 2019 Jun 1.

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11

Bhat, V., Allan, A.L., and Raouf, A. Role of the microenvironment in regulating normal and cancer stem cell activity: implications for breast cancer progression and therapy response. Cancers, 2019 Aug 24;11(9). pii: E1240. doi: 10.3390/cancers11091240.

Palma, D.A., Olson, R., Harrow, S., Correa, R., Schneiders, F., Haasbeek, C.J.A., Rodrigues, G.B., Lock, M., Yaremko, B., Bauman, G., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Louie, A., Chalmers, A., Warner, A., Slotman, B., de Gruijl, T.D., Allan, A., and Senan, S. (2019). Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET-10): Study Protocol for a Randomized Phase III Trial. BMC Cancer, 2019 Aug 19;19(1):816.

Ragab D, Sabra, S.A., Xia, Y., Goodale, D., Allan A.L., and Rohani, S. (2019). On-chip preparation of amphiphilic nano-micelles-in-sodium alginate spheroids (ANMs-in-SASs) as a novel platform against triple negative human breast cancer cells: fabrication, study of microfluidics flow hydrodynamics and proof of concept for anticancer and drug delivery. J. Pharm. Sci. 2019 Jul 25. pii: S0022-3549(19)30450-2.

Medeiros, B and Allan, A.L. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci, 2019, 20, 2272; doi:10.3390/ijms20092272.

Sabra, S.A., Sheweita, S.A., Haroun, M., Elzoghby, A.O., Ragab, D., Eldemellawy, M.A., Xia, Y., Goodale, D., Allan A.L., and Rohani, S. Magnetically-guided self-assembled protein micelles for targeted delivery of dasatinib to human triple negative breast cancer cells. J Pharm Sci. 2019 May;108(5):1713-1725.

Hotte, S.J., Eisenhauer, E.A., Joshua, A.M., Kumar, V., Ellard, S., Gregg, R.W., Mafarlane, R.J., Winquist, E., Torri, V., Reuther, J.D., Basappa, N.S., Kakumanu, A.S., North, S.A., Kollmannsberger, C.K., Tinker, A., Mirchandani, D., Tassignon, A., Hausman, D.F., Allan, A.L., Chi, K. (2019) NCIC CTG IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). Clin Genitourin Cancer. 2019 Mar 15. doi: 10.1016/j.clgc.2019.03.005. [Epub ahead of print; PMID: 31056399].

Dr. Anthony Nichols’ research “Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial” was published in Lancet Oncol October 2019 edition.

Research Associate Dr. Lihai Yu, recently published a paper in ACS Medicinal Chemistry Letters describing the first report of a PET imaging agent targeting the epigenetic modifier EZH2. This enzyme is relevant to numerous cancers including pancreatic ductal adenocarcinoma (PDAC) and is an important new target for anticancer drugs. This work is a collaboration of the labs of Dr. Chris Pin and Dr. Len Luyt. 18F-Labeled PET Probe Trageting Enhancer of Zeste Homologue 2 (EZH2) for Cancer Imaging.

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. 2019 May 1;5(5):681-688. doi:10.1004/jamaoncol.2018.6993. PMID: 30789648

Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects of inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients. Epub 2018 Dec 29. PMID:30773188